Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis - A pilot study

Journal of Breath Research

Volumn 12, Issue 1, 2018, Pages

  Rindlisbacher, Barbara ^a   Strebel, Carina ^b   Guler, Sabina ^a   Kollár, Attila ^a   Geiser, Thomas ^a   Martin Fiedler, Georg ^a   Benedikt Leichtle, Alexander ^a   Bovet, Cédric ^a   Funke Chambour, Manuela ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Hospital of Zweisimmen   (Switzerland)

Author keywords

exhaled breath condensate; idiopathic pulmonary fibrosis; mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; EXHALED BREATH CONDENSATE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; MALE; MASS SPECTROMETRY; METABOLOMICS; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BREATH ANALYSIS; DISCRIMINANT ANALYSIS; EXHALATION; LEAST SQUARE ANALYSIS; METABOLOME; PROCEDURES; REPRODUCIBILITY;

AGED; BIOMARKERS; BREATH TESTS; DISCRIMINANT ANALYSIS; EXHALATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LEAST-SQUARES ANALYSIS; MALE; METABOLOME; METABOLOMICS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS;

EID: 85040069420     PISSN: 17527155     EISSN: 17527163     Source Type: Journal    
DOI: 10.1088/1752-7163/aa840a     Document Type: Article

References (37)

1. Raghu G et al 2011 An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am. J. Respir. Crit. Care Med. 183 788-824
2. Ley B, Collard H R and King T E Jr 2011 Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 183 431-40
3. Kolb M and Shargall Y 2013 Lung surgery in interstitial lung disease-a safe and useful procedure? J. Thoracic Dis. 5 375-7
4. Raghu G et al 2015 An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline Am. J. Respir. Crit. Care Med. 192 e3-19
5. Funke M and Geiser T 2015 Idiopathic pulmonary fibrosis: the turning point is now! Swiss Med. Wkly 145 w14139
6. Myllarniemi M and Kaarteenaho R 2015 Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine Eur. Clin. Respir. J. 10 eCollection 2015
7. Martinez-Lozano Sinues P, Zenobi R and Kohler M 2013 Analysis of the exhalome: a diagnostic tool of the future Chest 144 746-9
8. Grob N M, Aytekin M and Dweik R A 2008 Biomarkers in exhaled breath condensate: a review of collection, processing and analysis J. Breath Res. 2 037004
9. Horvath I et al 2005 Exhaled breath condensate: methodological recommendations and unresolved questions Eur. Respir. J. 26 523-48
10. Kuban P and Foret F 2013 Exhaled breath condensate: determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review Anal. Chim. Acta 805 1-18
11. Rihak V, Zatloukal P, Chladkova J, Zimulova A, Havlinova Z and Chladek J 2010 Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis J. Clin. Lab. Anal. 24 317-22
12. Santini G et al 2016 Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers J. Breath Res. 10 017102
13. Borrill Z L, Roy K and Singh D 2008 Exhaled breath condensate biomarkers in COPD Eur. Respir. J. 32 472-86
14. Vestbo J et al 2008 Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE) Eur. Respir. J. 31 869-73
15. Antus B, Barta I, Csiszer E and Kelemen K 2012 Exhaled breath condensate pH in patients with cystic fibrosis Inflammation Res. 61 1141-7
16. Dent A G, Sutedja T G and Zimmerman P V 2013 Exhaled breath analysis for lung cancer J. Thoracic Dis. 5 S540-50
17. Psathakis K, Mermigkis D, Papatheodorou G, Loukides S, Panagou P, Polychronopoulos V, Siafakas N M and Bouros D 2006 Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis Eur. J. Clin. Invest. 36 362-7
18. de Laurentiis G, Paris D, Melck D, Montuschi P, Maniscalco M, Bianco A, Sofia M and Motta A 2013 Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate J. Proteome Res. 12 1502-11
19. Santini G et al 2016 Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease Curr. Top. Med. Chem. 16 1610-30
20. Malerba M and Montuschi P 2012 Non-invasive biomarkers of lung inflammation in smoking subjects Curr. Med. Chem. 19 187-96
21. Martinez-Lozano Sinues P, Meier L, Berchtold C, Ivanov M, Sievi N, Camen G, Kohler M and Zenobi R 2014 Breath analysis in real time by mass spectrometry in chronic obstructive pulmonary disease Respiration 87 301-10
22. Konstantinidi E M, Lappas A S, Tzortzi A S and Behrakis P K 2015 Exhaled breath condensate: technical and diagnostic aspects Sci. World J. 2015 435160
23. Beck O, Olin A C and Mirgorodskaya E 2016 Potential of mass spectrometry in developing clinical laboratory biomarkers of nonvolatiles in exhaled breath Clin. Chem. 62 84-91
24. Ley B et al 2012 A multidimensional index and staging system for idiopathic pulmonary fibrosis Ann. Intern. Med. 156 684-91
25. Dunn W B et al 2011 Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry Nat. Protocols 6 1060-83
26. Triba M N, Le Moyec L, Amathieu R, Goossens C, Bouchemal N, Nahon P, Rutledge D N and Savarin P 2015 PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters Mol. Biosyst. 11 13-9
27. Szymanska E, Saccenti E, Smilde A K and Westerhuis J A 2012 Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies Metabolomics 8 3-16
28. Benjamini Y and Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing J. R. Stat. Soc. B 57 289-300
29. Ruttkies C, Schymanski E L, Wolf S, Hollender J and Neumann S 2016 MetFrag relaunched: incorporating strategies beyond in silico fragmentation J. Cheminf. 8 3
30. Duhrkop K, Shen H, Meusel M, Rousu J and Bocker S 2015 Searching molecular structure databases with tandem mass spectra using CSI:FingerID Proc. Natl Acad. Sci. USA 112 12580-5
31. Shen H, Duhrkop K, Bocker S and Rousu J 2014 Metabolite identification through multiple kernel learning on fragmentation trees Bioinformatics 30 i157-64
32. Montesi S B, Mathai S K, Brenner L N, Gorshkova I A, Berdyshev E V, Tager A M and Shea B S 2014 Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis BMC Pulm. Med. 14 5
33. Chow S, Thomas P S, Malouf M and Yates D H 2012 Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis J. Breath Res. 6 016004
34. Horvath I et al 2017 A European Respiratory Society technical standard: exhaled biomarkers in lung disease Eur. Respir. J. 26 1600965
35. Montuschi P, Santini G, Valente S, Mondino C, Macagno F, Cattani P, Zini G and Mores N 2014 Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases J. Chromatogr. B 964 12-25
36. Ley B, Brown K K and Collard H R 2014 Molecular biomarkers in idiopathic pulmonary fibrosis Am. J. Physiol. Lung Cell. Mol. Physiol. 307 L681-91
37. Xia J and Wishart D S 2016 Using Metaboanalyst 3.0 for comprehensive metabolomics data analysis Curr. Protocols Bioinform. 55 14.10.1-91